What factors drive the global IV therapy and vein access market?

One key factor is the rise in healthcare spending in emerging markets.

The growing prevalence of chronic diseases, such as diabetes and cancer, is driving the intravenous (IV) therapy and vein access market to reach $74.4b by 2029 at a compound annual growth rate of 5.5%, according to BCC Research.

“This increase is due to ageing, unhealthy lifestyles and environmental factors, which put pressure on the global healthcare systems,” the report said.

The sector’s expansion is also attributed to a rise in healthcare spending in emerging markets, with significant investment directed towards hospitals, pharmaceuticals, and medical technology.

Moreover, alternative sites and home-based medical care are further driving market growth, with more patients allowed to receive treatment outside hospitals.

Meanwhile, IV solutions and sets are expected to dominate the market by the end of 2029.